Understanding Flu Vaccine Response in Pediatric Cancer Patients
This study looks at how well the seasonal flu vaccine works in children (up to 18 years old) who have a blood cancer (hematologic malignancy) and are receiving care at St. Jude Children's Research Hospital. Researchers want to see if these children develop a good immune response to the vaccine. This is important because flu can be very serious for children undergoing cancer treatment. You would be eligible if you have a blood cancer and are able to receive the current seasonal flu vaccine. The study aims to understand how many participants develop an immune response 3 to 5 weeks after vaccination, with results measured over 3 years. The current status of this study is unclear.
- Study design
- This is an observational study, meaning researchers will watch and collect information without providing any specific treatments. It plans to enroll 150 participants.
- What's involved
- You would have about one teaspoon of blood collected up to 6 times over a year. Researchers will also review your medical records for information on your condition, flu tests, and overall health.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will measure outcomes up to 3 years after vaccination.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Response to Influenza Vaccination in Pediatric Oncology Patients
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Ramilo Octavio, MD · PRINCIPAL_INVESTIGATOR · St. Jude Children's Research Hospital
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Proportion of evaluable participants.3 years
Feasibility is estimated as the proportion of evaluable patients who provide a baseline and Day +35 sample. A 95% confidence interval will be provided.
- Proportion of participants with immunogenicity 3 to 5 weeks following vaccination.3 years
Immunogenecity will be measured by the development of cell- and antibody-mediated influenza specific responses 3 to 5 weeks following vaccination. Immunogenicity is estimated as the proportion of evaluable patients whose cell- (as measured by development of any detectable specific T cell responses) and antibody-mediated influenza specific responses (as measured by detectable post vaccination antibody titers) 3 to 5 weeks following vaccination. 95% confidence intervals will be provided.